24-Hour Evaluation of the Effectiveness and Tolerability of Preservative-Free Tafluprost-Timolol Fixed Combination in Open-Angle Glaucoma or Ocular Hypertensive Patients Previously Treated with Preserved Latanoprost

References

• Holló G, Topouzis F, Fechtner RD. Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice. Exper Opin Pharmacother. 2014;15(12):1737–1747. doi:10.1517/14656566.2014.936850
   PubMed Web of Science ®Google Scholar
• Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17(5):350–355. doi:10.1097/IJG.0b013e31815c5f4f
   PubMed Web of Science ®Google Scholar
• Fechtner RD, Godfrey DG, Budenz D, Stewart JA, Stewart WC, Jasek MC. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea. 2010;29(6):618–621. doi:10.1097/ICO.0b013e3181c325b2
   PubMed Web of Science ®Google Scholar
• Katz G, Springs CL, Craven ER, Montecchi-Palmer M. Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost. Clin Ophthalmol. 2010;4:1253–1261. doi:10.2147/OPTH.S14113
   PubMedGoogle Scholar
• Ghosh S, O’Hare F, Lamoureux E, Vajpayee RB, Crowston JG. Prevalence of signs and symptoms of ocular surface disease in individuals treated and not treated with glaucoma medication. Clin Exp Ophthalmol. 2012;40(7):675–681. doi:10.1111/j.1442-9071.2012.02781.x
   PubMed Web of Science ®Google Scholar
• Li M, Gong L, Chapin WJ, Zhu M. Assessment of vision-related quality of life in dry eye patients. Invest Ophthalmol Vis Sci. 2012;53(9):5722–5727. doi:10.1167/iovs.11-9094
   PubMed Web of Science ®Google Scholar
• Tripathi BJ, Tripathi RC, Kolli SP. Cytotoxicity of ophthalmic preservatives on human corneal epithelium. Lens Eye Toxic Res. 1992;9(3–4).
   Google Scholar
• Steven DW, Alaghband P, Lim KS. Preservatives in glaucoma medication. Br J Ophthalmol. 2018;102(11):1497–1503. doi:10.1136/bjophthalmol-2017-311544
   PubMed Web of Science ®Google Scholar
• Liton PB, Challa P, Stinnett S, Luna C, Epstein DL, Gonzalez P. Cellular senescence in the glaucomatous outflow pathway. Exp Gerontol. 2005;40(8–9):745–748. doi:10.1016/j.exger.2005.06.005
   PubMed Web of Science ®Google Scholar
• Toussaint O, Medrano EE, von Zglinicki T. Cellular and molecular mechanisms of stress-induced premature senescence (SIPS) of human diploid fibroblasts and melanocytes. Exp Gerontol. 2000;35(8):927–945. doi:10.1016/s0531-5565(00)00180-7
   PubMed Web of Science ®Google Scholar
• Freeman PD, Kahook MY. Preservatives in topical ophthalmic medications: historical and clinical perspectives. Exp Rev Ophthalmol. 2009;4(1):59–64. doi:10.1586/17469899.4.1.59
   Google Scholar
• European Glaucoma Society Terminology and Guidelines for Glaucoma, 5th Edition. Br J Ophthalmol. 2021;105(Suppl 1):1–169. doi:10.1136/bjophthalmol-2021-egsguidelines
   Web of Science ®Google Scholar
• Chalmers RL, Begley CG, Caffery B. Validation of the 5-Item Dry Eye Questionnaire (DEQ-5): discrimination across self-assessed severity and aqueous tear deficient dry eye diagnoses. Cont Lens Anterior Eye. 2010;33(2):55–60. doi:10.1016/j.clae.2009.12.010
   PubMed Web of Science ®Google Scholar
• Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea. 2003;22(7):640–650. doi:10.1097/00003226-200310000-00008
   PubMed Web of Science ®Google Scholar
• Rossi GCM, Milano G, Tinelli C. The Italian version of the 25-item National Eye Institute Visual Function Questionnaire: translation, validity, and reliability. J Glaucoma. 2003;12(3):213–220. doi:10.1097/00061198-200306000-00006
   PubMed Web of Science ®Google Scholar
• R: The R Project for Statistical Computing. Availabe from: https://www.r-project.org/. Accessed January 4, 2024
   Google Scholar
• Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using lme4. J Statisl Soft. 2015;67:1–48. doi:10.18637/jss.v067.i01
   Web of Science ®Google Scholar
• Lenth RV. Least-Squares Means: the R Package lsmeans. J Statisl Soft. 2016;69:1–33. doi:10.18637/jss.v069.i01
   Web of Science ®Google Scholar
• Kitamura K, Chiba T, Mabuchi F, et al. Efficacy and Safety of Switching Prostaglandin Analog Monotherapy to Tafluprost/Timolol Fixed-Combination Therapy. J Ophthalmol. 2018;2018:8456764. doi:10.1155/2018/8456764
   PubMed Web of Science ®Google Scholar
• Inoue K, Masumoto M, Ishida K, Tomita G. Efficacy and Safety of Switching from Prostaglandin Analog Therapy to Prostaglandin / Timolol Fixed Combination or Prostaglandin / Brimonidine Therapy. Open Ophthalmol J. 2017;11:156–163. doi:10.2174/1874364101711010156
   PubMedGoogle Scholar
• Stalmans I, Lemij H, Clarke J, Baudouin C. Signs and symptoms of ocular surface disease: the reasons for patient dissatisfaction with glaucoma treatments. Clin Ophthalmol. 2020;14:3675–3680. doi:10.2147/OPTH.S269586
   PubMed Web of Science ®Google Scholar
• Baudouin C, Denoyer A, Desbenoit N, Hamm G, Grise A. In vitro and in vivo experimental studies on trabecular meshwork degeneration induced by benzalkonium chloride (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2012;110:40–63. doi:10.1155/2010/939602.
   PubMedGoogle Scholar
• Batra R, Tailor R, Mohamed S. Ocular surface disease exacerbated glaucoma: optimizing the ocular surface improves intraocular pressure control. J Glaucoma. 2014;23(1):56–60.
   PubMed Web of Science ®Google Scholar
• Oddone F, Kirwan J, Lopez-Lopez F, et al. Switching to preservative-free tafluprost/timolol fixed-dose combination in the treatment of open-angle glaucoma or ocular hypertension: subanalysis of data from the visionary study according to baseline monotherapy Treatment. Adv Ther. 2022;39(8):3501–3521. doi:10.1007/s12325-022-02166-6
   PubMed Web of Science ®Google Scholar
• Pfeiffer N, Traverso CE, Lorenz K, et al. A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components. Adv Ther. 2014;31(12):1228–1246. doi:10.1007/s12325-014-0163-3
   PubMed Web of Science ®Google Scholar
• Liu JHK, Kripke DF, Weinreb RN. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure. Am J Ophthalmol. 2004;138(3):389–395. doi:10.1016/j.ajo.2004.04.022
   PubMed Web of Science ®Google Scholar
• Konstas AGP, Nakos E, Tersis I, Lallos NA, Leech JN, Stewart WC. A comparison of once-daily morning vs evening dosing of concomitant latanoprost/timolol. Am J Ophthalmol. 2002;133(6):753–757. doi:10.1016/s0002-9394(02)01460-5
   PubMed Web of Science ®Google Scholar
• Rossetti L, Karabatsas CH, Topouzis F, et al. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure. Ophthalmology. 2007;114(12):2244–2251. doi:10.1016/j.ophtha.2007.01.025
   PubMed Web of Science ®Google Scholar
• Menon IA, Trope GE, Basu PK, Wakeham DC, Persad SD. Binding of timolol to iris-ciliary body and melanin: an in vitro model for assessing the kinetics and efficacy of long-acting antiglaucoma drugs. J Ocul Pharmacol. 1989;5(4):313–324. doi:10.1089/jop.1989.5.313
   PubMedGoogle Scholar
• Konstas AG, Katsanos A, Athanasopoulos GP, et al. Preservative-free tafluprost/timolol fixed combination: comparative 24-h efficacy administered morning or evening in open-angle glaucoma patients. Exper Opin Pharmacother. 2018;19(18):1981–1988. doi:10.1080/14656566.2018.1534958
   PubMed Web of Science ®Google Scholar
• Hopf S, Schwantuschke D, Schmidtmann I, Pfeiffer N, Hoffmann EM. Impact of intraocular pressure fluctuations on progression of normal tension glaucoma. Int J Ophthalmol. 2021;14(10):1553–1559. doi:10.18240/ijo.2021.10.12
   PubMed Web of Science ®Google Scholar
• Bengtsson B, Heijl A. Diurnal IOP fluctuation: not an independent risk factor for glaucomatous visual field loss in high-risk ocular hypertension. Graefes Arch Clin Exp Ophthalmol. 2005;243(6):513–518. doi:10.1007/s00417-004-1103-8
   PubMed Web of Science ®Google Scholar
• Kim SH, Lee EJ, Han JC, Sohn SW, Rhee T, Kee C. The Effect of Diurnal Fluctuation in Intraocular Pressure on the Evaluation of Risk Factors of Progression in Normal Tension Glaucoma. PLoS One. 2016;11(10):e0164876. doi:10.1371/journal.pone.0164876
   PubMed Web of Science ®Google Scholar
• De Moraes CG, Jasien JV, Simon-Zoula S, Liebmann JM, Ritch R. Visual field change and 24-hour IOP-Related Profile with a contact lens sensor in treated glaucoma patients. Ophthalmology. 2016;123(4):744–753. doi:10.1016/j.ophtha.2015.11.020
   PubMed Web of Science ®Google Scholar
• Matlach J, Bender S, König J, Binder H, Pfeiffer N, Hoffmann EM. Investigation of intraocular pressure fluctuation as a risk factor of glaucoma progression. Clin Ophthalmol. 2018;67:9–16. doi:10.18637/jss.v067.i01
   Google Scholar
• Kim DW, Shin J, Lee CK, Kim M, Lee S, Rho S. Comparison of ocular surface assessment and adherence between preserved and preservative-free latanoprost in glaucoma: a parallel-grouped randomized trial. Sci Rep. 2021;11(1):14971. doi:10.1038/s41598-021-94574-x
   PubMed Web of Science ®Google Scholar
• Ranno S, Fogagnolo P, Rossetti L, Orzalesi N, Nucci P. Changes in corneal parameters at confocal microscopy in treated glaucoma patients. Clin Ophthalmol. 2011;5:1037–1042. doi:10.2147/OPTH.S22874
   PubMedGoogle Scholar
• Agnifili L, Brescia L, Villani E, et al. In vivo confocal microscopy of the corneal sub-basal nerve plexus in medically controlled glaucoma. Microsc Microan. 2022:1–8. doi:10.1017/S1431927621013969
   PubMed Web of Science ®Google Scholar
• Sarkar J, Chaudhary S, Namavari A, et al. Corneal neurotoxicity due to topical benzalkonium chloride. Invest Ophthalmol Vis Sci. 2012;53(4):1792–1802. doi:10.1167/iovs.11-8775
   PubMed Web of Science ®Google Scholar
• Mastropasqua R, Agnifili L, Fasanella V, et al. In vivo distribution of corneal epithelial dendritic cells in patients with glaucoma. Invest Ophthalmol Vis Sci. 2016;57(14):5996–6002. doi:10.1167/iovs.16-20333
   PubMed Web of Science ®Google Scholar
• Lee OL, Tepelus TC, Huang J, et al. Evaluation of the corneal epithelium in non-Sjögren’s and Sjögren’s dry eyes: an in vivo confocal microscopy study using HRT III RCM. BMC Ophthalmol. 2018;18(1):309. doi:10.1186/s12886-018-0971-3
   PubMedGoogle Scholar
• Canadian Ophthalmological Society Glaucoma Clinical Practice Guideline Expert Committee, Canadian Ophthalmological Society. Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of glaucoma in the adult eye. Can J Ophthalmol. 2009;44(1):S7–93. doi:10.3129/cjo44s1
   PubMedGoogle Scholar
• Goldberg I. Asia Pacific Glaucoma Guidelines. J Ophthal. 2005;7:126–130.
   Google Scholar
• Netland PA, Weiss HS, Stewart WC, Cohen JS, Nussbaum LL. Cardiovascular effects of topical carteolol hydrochloride and timolol maleate in patients with ocular hypertension and primary open-angle glaucoma. Night Study Group. Am J Ophthalmol. 1997;123(4):465–477. doi:10.1016/s0002-9394(14)70172-2
   PubMed Web of Science ®Google Scholar
• Hayreh SS, Podhajsky P, Zimmerman MB. Beta-blocker eyedrops and nocturnal arterial hypotension. Am J Ophthalmol. 1999;128(3):301–309. doi:10.1016/s0002-9394(99)00160-9
   PubMed Web of Science ®Google Scholar
• Graham SL, Drance SM. Nocturnal hypotension: role in glaucoma progression. Surv Ophthalmol. 1999;43(Suppl 1):S10–16. doi:10.1016/s0039-6257(99)00016-8
   PubMedGoogle Scholar